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ABSTRACT 
 Environmental exposure to arsenic is a worldwide health concern which is linked 
to a number of diseases.  Areas with arsenic levels above the current safe 
concentration have higher levels of skin, lung, liver, and bladder cancers and non-
carcinogenic pathologies, including neuropathy, cardiovascular diseases and diabetes 
mellitus.  Understanding the mechanism by which arsenic exerts its toxic effects is 
crucial to developing preventative strategies and more effective treatments for 
individuals with long term exposure to arsenic compounds. 
 This thesis outlines the epidemiological evidence for arsenic-linked diseases as 
well as the current understanding of arsenic metabolism and the mechanism(s) of how 
arsenic exerts its cytotoxicity. 
 The liver is a major site of arsenic uptake and biotransformation and thus is 
affected by high arsenic levels.  Generation of reactive oxygen species (ROS) has been 
shown to play a major role in the toxic effects of arsenic.  Using primary and 
immortalized hepatocyte cell lines these studies investigate how arsenic generates the 
production of ROS.  The localization of superoxide was shown to overlap with 
mitochondria and antioxidant enzymes were shown to be induced after arsenic 
treatment.  Measurement of mitochondria function through oxygen consumption rate 
(OCR) shows that arsenic affects oxidative phosphorylation and the ability for 
mitochondria to efficiently couple electron transport with ATP production.  
Understanding the source of ROS from arsenic exposure and how cells cope with 
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altered mitochondrial bioenergetics is an important building block for future studies on 
arsenic toxicity and for developing treatments for arsenic exposure.   
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Chapter 1: BACKGROUND AND INTRODUCTION  
2 
 
1.1 Arsenic as a human health hazard 
ENVIRONMENTAL EXPOSURE TO ARSENIC 
Arsenic is a metalloid naturally present in the Earth’s crust.  Its presence in the soil 
results in the contamination of drinking water from ground sources, the primary route of 
exposure to humans (1).  Consumption of food grown in soil with high arsenic levels is 
another major source to humans (2).  Seafood may also be another route of exposure, 
however the typical concentration and form of arsenic in seawater presents a lesser 
problem.  Industrial exposure remains of importance, although efforts to remove it from 
industrial processes in the last thirty years have improved.  Arsenic has been used in 
the making of pigments, pesticides and chemical warfare agents.  Its use in industrial 
processes has presented a source of exposure by inhalation routes through arsine gas 
production.  Arsenic concentrations vary between regions, with some areas having little 
to no detection.  However many countries, such as Bangladesh, India, China, Argentina 
and the United States have areas with arsenic levels that are considered hazardous (3).  
The World Health Organization (WHO) initially recommended arsenic levels in water not 
exceed 0.05 mg/L, or 50 ppb, but lowered the limit to 10 ppb in 1992 as evidence 
accrued demonstrating the carcinogenic effects of arsenic at low concentrations (4,5).  
The US limit set by the Environmental Protection Agency (EPA) was adjusted to 10 ppb 
in 2006 (6).  In the world, over 100 million people are exposed to unhealthy levels of 
arsenic (7).  Many community water sources exceed this limit, and a search for 
alternative water sources or methods to remove arsenic from water is of high 
importance. 
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EPIDEMIOLOGICAL EVIDENCE LINKING ARSENIC EXPOSURE TO HUMAN 
HEALTH 
Arsenic exposure has been implicated in a variety of health hazards.  Arsenic-
associated diseases have been linked to chronic exposure of arsenic levels even below 
the WHO’s recommendation of 10 ppb (8).  Epidemiological studies show higher cases 
of skin, lung, liver, and bladder tumors in areas with high levels of arsenic in the water 
supply compared with the general population or areas with low arsenic exposure.  Skin 
and bladder tumors are particularly common.  Because of this, inorganic arsenic has 
been classified as a carcinogen by the WHO and EPA.  Reviews of epidemiological 
studies from Argentina, Taiwan and the United States concluded that bladder cancer 
diagnoses and deaths were higher in these areas with arsenic-contaminated well water 
(9).  More convincingly, when tap water systems which removed arsenic were 
implemented, there was an eventual gradual decrease in bladder cancer-related deaths.  
Meta-analysis has recently shown that the standardized mortality ratio (SMR) is 
significantly increased with respect to liver cancer mortalities reported in high-level 
arsenic areas (10). 
In addition to carcinogenic effects, arsenic is implicated in numerous nonmalignant 
diseases.  Peripheral vascular disease, cardiovascular disease, skin lesions, and 
diabetes mellitus are several important results of sustained arsenic exposure.  In areas 
with high-chronic exposure (>0.05 mg/L), cardiovascular disease, coronary heart 
disease, stroke, and peripheral arterial disease were 32, 89, 8, and 17% more likely to 
occur (8).  A meta-analysis of epidemiological studies in China on the occurrence of 
4 
 
type 2 diabetes mellitus suggested that risk for type 2 diabetes increased by 13% for 
every 100 µg/L increment of inorganic arsenic in drinking water (10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
1.2 Mechanisms of arsenic toxicity  
METABOLISM OF ARSENIC  
Arsenic is found within soil and water primarily as pure, oxide, sulfur, or compounded 
with metals.  Oxides are the most common arsenic species in drinking water and are 
most correlated with toxicity.  The trioxide and pentoxide forms of arsenic are well 
absorbed through oral and inhalation routes, and transdermal exposure is another 
possible entry of arsenic.  All these routes pass eventually through the liver, where 
hepatocytes take up arsenite (trioxide form) and arsenate (pentoxide form) (1).  
Aquaporin 9 has been strongly linked to intracellular accumulation of arsenic in primary 
mouse hepatocytes (11,12).  It has been shown that inhibition of aquaporin 9 reduces 
cellular concentration of arsenic, while overexpression increases arsenic toxicity.  A 
series of biotransformation and detoxification reactions take place in the liver to 
enhance excretion (13,14).  Arsenic pentoxide is reduced to arsenic trioxide by an 
arsenate reductase, purine nucleoside phosphorylase.  With S-adenosylmethionine as a 
methyl donor, a series of methylations and reductions occur by arsenite/MMAIII 
(monomethylarsenous acid) methyltransferase and MMAV reductase, respectively (15) 
(Figure 1).  Glutathione is used for the reduction reactions in between methylations.  A 
mixture of mono-, di-, and tri-methylated forms of arsenic are formed and readily 
excreted in the urine.  The average proportions of these forms in human urine are 10-
30% inorganic arsenic, 10-20% MMA and 60-80% dimethylarsenous acid (DMA) (15).  
These methylated species may exert some toxicity on hepatocytes, but the (III) and (V) 
oxides have shown the most potential for toxic effects (1).  Multidrug resistance-
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associated protein 1 (MRP-1) has been implicated in arsenic resistance and as a 
transporter responsible for efflux of arsenite-glutathione conjugates (16,17).   The sites 
of absorption that receive the highest exposure to toxic arsenic concentrations are skin, 
lung, liver, and bladder.  The higher incidences of cancer in these organs suggest a 
strong correlation. 
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Figure 1. Known pathways of arsenic metabolism in vertebrates (18). 
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EVIDENCE FOR OXIDATIVE STRESS IN ARSENIC-INDUCED TOXICITY AND 
CARCINOGENICITY 
Myriad toxic effects are seen intracellularly with arsenic poisoning.  Stable As-S bonds 
can occur with sulfur groups within proteins to inhibit enzymes (19).  Pyruvate 
dehydrogenase, succinic dehydrogenase, glutathione reductase, and thioredoxin 
reductase inhibition by arsenite have been reported (20-22).  Unstable arsenoesters can 
form from interactions of arsenate with the phosphate groups within ATP, disrupting the 
bioenergetic profile of the cell (13).  Inhibition of key antioxidant and metabolic enzymes 
provide strong evidence for the production of reactive oxygen species (ROS) seen from 
arsenic poisoning. 
Production of ROS is suggested to be a major source of the toxic effects seen from 
arsenic.  Oxidative stress is known to be involved in the degradation of cellular 
macromolecules, such as lipid peroxidation and DNA damage.  Disturbing enzyme 
activity and production of various ROS (H2O2, OH
-, ROO·, O2
-) is hypothesized to be a 
source of genotoxicity that produces hyperplasia and cancer phenotypes (23,24).  
Inhibition of DNA ligase, chromosomal aberrations, altered DNA methylation, and 
activation of the mitogen activated protein kinase pathway are avenues that have been 
explored to provide causes of increased cell proliferation frequently seen with chronic 
arsenic exposure (13,25). 
If the antioxidant response of the cell is sufficient to detoxify arsenic species and its 
ROS byproducts, cellular adaptation will allow survival of affected cells and prevent 
organ damage.  A primary mechanism of antioxidant response is via the Nrf2-Keap1 
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pathway.  The transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2) is 
normally sequestered and ubiquitinated in the cytoplasm.  Accumulated ROS disrupts 
Nrf2-Keap1 and as a result Nrf2 accumulates and translocates to the nucleus (26).   
Nrf2 forms a heterodimer with a small Maf protein to bind the Antioxidant Response 
Element (ARE) in the promoter region of target genes.  Genes regulated by this 
pathway include enzymes that reduce oxidative stress, phase I and II metabolism 
enzymes, and transporters.  Heme oxygenase-1 (HO-1) is regulated by Nrf2 and is 
highly inducible in response to arsenic.  Previous studies show HO-1 to exert a 
protective effect from oxidative stress by positive feedback with Nrf2 (27).  As such, HO-
1 provides an established positive control to indicate ROS and arsenic poisoning (28). 
Despite consistent observation of arsenic-induced ROS, little is known about the 
components and origins of arsenic induced mammalian oxidative stress.  Understanding 
the origins and mechanism by which arsenic induces oxidative stress could open up 
potentially new therapeutic avenues for prevention and intervention strategies against 
the toxic effects of arsenic. 
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1.3 Mitochondrial dysfunction in normal and pathophysiology 
MITOCHONDRIA AND ARSENIC 
Mitochondria are the largest source of ATP production and are very sensitive to the 
oxidative state of the cell.  Under normal conditions a proton gradient is built from the 
transfer of electrons from various electron donors, with molecular oxygen being the final 
electron acceptor.  The established proton gradient is coupled to the production of ATP 
from ADP.  While this provides the cell with a large portion of its ATP pool, there are 
many points in this process where reactive by-products can be produced (29).  Electron 
transfer to oxygen must be tightly controlled or electron “leaking” can result in 
superoxide production, a highly reactive oxygen species (30).  Malfunction of electron 
transfer not only reduces the cell’s available ATP, the ROS produced from this reacts 
with many cellular macromolecules.  Excessive cellular damage will initiate apoptosis or 
give rise to a variety of pathological conditions (31,32).  Mitochondrial diseases may be 
inherited or induced and result in a variety of pathologies, including diabetes mellitus, 
various neuropathies and myopathies (33,34). 
ROS can perturb the function of mitochondria, the principal source of oxygen radicals 
under normal conditions.  The role of ROS in arsenic toxicity has been shown by 
suppression of ROS generation.  Pretreatment of myoblasts with N-acetylcysteine 
(NAC) before sodium arsenite treatment resulted in suppressed lipid peroxidation, ER 
stress, caspase cascade activity and apoptosis (35).  Arsenic is known to alter 
mitochondrial membrane potential and disrupt electron transport, particularly by altered 
activity of complex I (36).  Altered activity of complex I and III of the electron transport in 
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particular is associated with an increase in mitochondrial ROS (37,38).  Isolated rat 
hepatocytes show decreased complex I activity when treated with sodium arsenite (39).  
With ROS playing an important role in the occurrence of many diseases and 
pathologies and mitochondria being a large source of intracellular ROS, it is important to 
investigate and link the production of mitochondrial ROS to arsenic toxicity.  Previous 
studies strongly suggest the alteration of mitochondria function plays a key role in the 
development of various diseases and systemic effects associated with arsenic.   
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Chapter 2: EXPERIMENTAL MATERIALS AND METHODS 
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CELL CULTURE 
Human liver-derived cell lines Hep3B and HepG2 were from the American Type Culture 
Collection (Manassas, VA). Cells were cultured in modified Eagle’s medium 
supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 2mM L-
glutamine.  Mouse primary hepatocytes were plated and grown in Williams’ Medium E 
supplemented with 10% FBS and 100 units/ml penicillin and streptomycin for 3 hours 
before replacing with serum-free Williams’ Medium E.  For arsenic treatment, culture 
medium was replaced with fresh media containing the appropriate concentration of 
sodium arsenite dissolved in water and incubated at 37°C for 16 hours.  All chemicals 
were from Sigma-Aldrich Corporation (St Louis, MO) unless otherwise stated. 
 
LIVE CELL IMAGING 
HepG2 cells were cultured overnight in chamber slides in increasing concentrations of 
arsenic.  Culture medium was replaced with PBS containing 5 µM mitoSOX (Invitrogen), 
1µM mitoTracker green (Life Technologies), and 0.5 µM Hoechst 33342 (Invitrogen) 
and incubated at 37°C for 15 minutes before washing 3 times with PBS.  Slides were 
mounted and viewed at excitation/emission of 510/580 nm (mitoSOX), 490/516 nm 
(mitoTracker green) and 350/450 nm (Hoechst). 
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ISOLATION OF PRIMARY HEPATOCYTES 
Primary human hepatocytes were isolated by the Cell Isolation Core at University of 
Kansas Medical Center as described by Xie, et al. (40). 
 
 
 
 
CYTOTOXICITY ASSAY 
In 96-well plates, HepG2 cells, primary mouse or human hepatocytes were seeded with 
15,000 cells/well and kept at 37°C for one day.  Then, media was replace with media 
containing sodium arsenite in water in a dilution series or with vehicle for 2 days. We 
assessed cytotoxicity by using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide assay as described (28,41).  Briefly, 1 mg/ml MTT was added to each well and 
incubated at 37°C for 2-4 hours until color developed.  Media was removed and 
replaced with 0.04M HCl in isopropanol.  The plate was mixed on a shaker for 15 
minutes and read absorbance at 590 nm.  IC50 values were calculated based off 
absorbance and arsenite concentration. 
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REAL-TIME PCR AND WESTERN ANALYSIS 
RNA isolation, Reverse transcription and Real-Time PCR analysis. RNA was isolated 
using TRIZOL® reagent (Invitrogen, Grand Island, NY). One μg of RNA was used for 
reverse transcription using iScriptTM cDNA synthesis kit, following the manufacturer’s 
protocol (BioRad, CA). Real-time PCR was performed using CFX384TM Real Time 
PCR System (BioRad, CA) as described previously using primer sets specific for the 
mouse or human genes (42) GCK, HK-2, PFK, GCLC, GCLM, GSS, GSTP1, GSTT1, 
actin, or GAPDH.  
For Western analysis, cell lysates were prepared in 1x RIPA buffer with protease 
inhibitors (Roche Applied Science) and 15 µg of total protein was analyzed by 
polyacrylamide gel electrophoresis (PAGE). Polyclonal primary antibodies were used to 
detect SOD2 (Abcam; Cat #ab13533, Cambridge, MA), Catalase (Cell Signalling, Cat 
#8841, Danvers, MA), GAPDH (Cell Signaling, Cat #2118), Actin (Sigma-Aldrich, Cat 
#A5441, St Louis, MO), HO-1 (Enzo Life Sciences, Cat #ADI-SPA-895, Farmingdale, 
NY), OXPHOS cocktail (Abcam, mouse #ab110413, human #ab13533).  
Immunoreactive proteins were detected using polyclonal goat antirabbit horseradish 
peroxidase IgG secondary antibodies (Thermo Scientific, Waltham, MA) and visualized 
using Supersignal™ chemiluminescent horseradish peroxidase substrate (Thermo 
scientific, MA). Densitometric analysis was performed using ImageJ analysis software 
(NIH). 
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COMPLEX I AND PYRUVATE DEHYDROGENASE ACTIVITY ASSAY 
Complex I and PDH activity was measured using the Complex I Enzyme Dipstick Assay 
kit or PDH Enzyme Dipstick Assay kit from abcam (Cambridge, UK) as per the protocol.  
50 µg protein was immuno-captured using a dipstick with anti-human or anti-mouse 
complex I or PDH antibody.  Activity was measured by densitometry using ImageJ 
(NIH). 
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MITOCHONDRIA STRESS TESTS 
Oxygen consumption rate (OCR) was measured in real-time, in an XF24x3 Extracellular 
Flux Analyzer (Seahorse Bioscience, Billerica, MA). HepG2 cells or mouse primary 
hepatocytes were seeded in XF24-well plates (50,000 cells per well in 100 μl). After 6 h, 
400 μl media with sodium arsenite was added to achieve a final concentration of 0, 2.5, 
5 and 10 µM arsenic (n=5 wells). Cells were further incubated overnight at 37°C, 5% 
CO2. The XF24 sensor cartridge was hydrated with 1 ml calibration buffer per well 
overnight at 37°C. The sensor cartridge was loaded with oligomycin (1 μM, port A), 
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP, 0.5 μM, port B) and 
rotenone plus antimycin-A (1 μM each, port C) to measure the bioenergetic profile. Cells 
were washed twice with pre-warmed XF assay medium containing 25 mM glucose and 
incubated in XF assay medium at 37°C without CO2. Once the sensor cartridge was 
equilibrated, the calibration plate was replaced with the cell plate to measure OCR using 
mitoStress application. 
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ATP LEVEL MEASUREMENT BY HPLC 
Extraction of ATP from cells: Six-well plates seeded with 1 x 106 cells were treated with 
different concentrations of arsenic for 16 hr. Cells were lysed with 0.5 ml of 0.5M 
perchloric acid on ice for 5 min. The extraction mixture was centrifuged at 16,000 x g for 
10 min at 4°C. Three hundred microliters of supernatant was quickly neutralized to ~pH 
6.0 with 4M potassium dichromate. The neutralized supernatant was incubated for 30 
min on ice to precipitate potassium perchlorate which was removed by centrifugation at 
16,000 x g for 10 min at 4°C. The supernatant was stored at -80°C until further analysis.  
ATP Standards: ATP standards were made in 0.5M perchloric acid neutralized with 
potassium dichromate as described above. Fifty microliters of sample was used for the 
HPLC analysis. ATP standards were linear for the dilution range used in this study (0.5 
µM – 1 mM). 
HPLC analysis: The HPLC instrument (Schimadzu Instruments Inc., USA) was 
equipped with an LC-20AD pump system and SPD-M20A diode array detector was 
used. SupelcosilTM LC-18 150 x 4.6 mm column (5µm particle size) was used for 
separation of analytes. HPLC separation was achieved using gradient elution. Mobile 
phase A and B consisted of 0.1M monopotassium phosphate and 0.008M 
tetrabutylammonium hydrogen sulfate dissolved in deionized water and  adjusted to 
pH= 6.0. Two percent acetonitrile was added to mobile phase A while mobile phase B 
consisted of 30% acetonitrile. The elution program was as follows: 2.5 min 100% A, 0% 
B; 3.5 min 90% A, 10% B; 1 min 80% A, 20% B; 5 min 60% A, 40% B; 8 min 0% A, 
100% B and 10 min 100% A, 0% B. Flow rate of the mobile phase was 1 ml/min, while 
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the injection volume was 50 µl. The autosampler was set at 4°C and the column was 
maintained at 30°C. ATP in the samples was identified by comparison with the retention 
time of the standard (~7 min), while the concentration was determined using an external 
standard method.   
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Chapter 3: RESULTS 
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3.1 VIABILITY OF HUMAN AND MOUSE PRIMARY HEPATOCYTES AND HUMAN 
HEPATOMA CELLS AFTER EXPOSURE TO INORGANIC SODIUM ARSENITE 
Although much information is available on the toxicity profile of arsenic in cultured cell 
lines, very little is known about the toxicity profile of arsenic in human and mouse 
primary hepatocytes. Thus, in these studies we first established the IC50 values for 
sodium arsenite in human and mouse primary hepatocytes and compared it to the 
toxicity profile in human hepatoma HepG2 cells. Mouse and human primary 
hepatocytes and HepG2 cells were treated with increasing concentrations of sodium 
arsenite (0 – 100µM) for 16 hours. At the end of treatment viability was evaluated by the 
MTT assay as described in the methods. Human primary hepatocytes were significantly 
more resistant to sodium arsenite treatment compared to either mouse primary 
hepatocytes or human hepatoma HepG2 cells. The order of resistance increased with 
mouse primary hepatocytes < HepG2 cells < human primary hepatocytes (Table 1). 
Sodium arsenite was also non-lethal to all three cell types up to a concentration of 20 
µM for a maximum exposure time of 16 h. Based on these initial observations an 
exposure regimen of 0 – 20 µM for 16 h was considered as non-lethal to both primary 
hepatocytes and human hepatoma cells, and was employed as the treatment regimen 
in the rest of the studies. 
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Table 1. Sodium arsenite IC50 values of human hepatoma cells (HepG2), mouse 
and human primary hepatocytes.  HepG2 cells, human primary hepatocytes (HPH) 
and mouse primary hepatocytes (MPH) were exposed to increasing concentrations of 
sodium arsenate (0 µM to 100 µM) for 16 h. Arsenate toxicity was evaluated by 
measuring cell death using the MTT assay as described in methods.  
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3.2 DOSE AND TIME DEPENDENT EFFECT OF SODIUM ARSENATE ON 
MITOCHONDRIAL FUNCTION.                                                                           
Experimental evidence indicates that exposure to arsenic induces oxidative stress. 
Further, given the prominent role of mitochondria in the generation of reactive oxygen 
species (ROS), it has been suggested that mitochondria are the major source of ROS 
production in cells following arsenic exposure. Based on these observations, we 
hypothesized that mitochondrial dysfunction following exposure to arsenic may be 
associated with the generation of ROS. To assess this, we evaluated mitochondrial 
function in mouse primary hepatocytes and hepatoma cells in response to the non-lethal 
concentrations of sodium arsenate described above. Mitochondrial function was 
evaluated using the Seahorse extracellular flux analyzer, which allows for real-time 
measurements of oxygen consumption and provides an overall assessment of the 
bioenergetics function of the cell.  Arsenic decreased both basal and mitochondrial 
respiratory rate in a dose dependent manner (Figure 2A, C and D and Figure 3A, B). In 
addition, we found that arsenic dose dependently decreased coupling efficiency (Figure 
2F and 3D) and spare respiratory capacity (Figure 2E and 3C) and increased proton 
leak (Figure 2G) in both hepatoma cells (Figure 2) and primary hepatocytes (Figure 3) . 
These results suggest that even at concentrations as low as 2.5 µM, arsenic treatment 
results in altered mitochondrial function. 
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Figure 2. Sodium arsenite decreases mitochondrial coupling and increases 
proton leak in human hepatoma (HepG2) cells in a dose dependent manner. 
OXPHOS was manipulated with injections of oligomycin (1 µM), FCCP (0.5 µM), and 
rotenone plus antimycin-A (1 µM each). Bioenergetics profile (A) and percent OCR (B) 
of HepG2 cells treated with 2.5, 5 and 10 µM of sodium arsenite for 16 h. Arsenic 
treatment altered basal OCR (C), mitochondrial OCR (D), reserve capacity (E), ATP-
linked respiration (F), proton leak (G) and non-mitochondrial respiration (H).  Reserve 
capacity was calculated from the difference between the maximal and basal OCR.  
ATP-linked respiration is the difference between the oligomycin-induced decrease in 
OCR.  Proton leak was the difference between ATP-linked respiration and non-
mitochondrial respiration.  Non-mitochondrial OCR was determined by injecting 
rotenone plus antimycin-A simultaneously to fully inhibit the electron transport chain. 
Results are mean ± SEM. Results are representative of three independent experiments. 
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n=5 per group. “*” Significantly different from control (vehicle treated), p < 0.05. “#” 
Significantly different from 2.5 µM sodium arsenite treated, p < 0.05. 
 
 
 
 
 
 
 
 
 
 
26 
 
 
Figure 3. Sodium arsenite decreases mitochondrial coupling and increases 
proton leak in mouse primary hepatocytes (MPH) in a dose dependent manner. 
OXPHOS was manipulated with injections of oligomycin (1 µM), FCCP (0.5 µM), and 
rotenone plus antimycin-A (1 µM each). MPH cells treated with 2.5, 5 and 10 µM of 
sodium arsenite for 16 h demonstrated altered basal OCR (B), reserve capacity (C), and 
ATP-linked respiration (D). Reserve capacity and ATP-linked respiration were 
calculated as described in Figure 1 for HepG2 cells.  Basal respiratory rates decreased 
with arsenic treatment with statistical significant differences seen only with the initial 
dose.  Results are mean ± SEM. Results are representative of three independent 
experiments. n=5 per group.  
 
 
27 
 
3.3 EFFECT OF SODIUM ARSENITE ON ELECTRON TRANSPORT CHAIN (ETC) 
EXPRESSION AND ACTIVITY IN HEPATOCYTES 
Decrease in coupling efficiency and increased proton leak following exposure to sodium 
arsenite could result either from a decrease in ATP demand, a lack of substrate 
availability, or damage to the ETC, which would impede the flow of electrons. To 
explore this further and to understand the mechanism by which arsenic reduces 
coupling efficiency, we first evaluated the ATP levels in HepG2 cells and in primary 
hepatocytes treated with arsenic.  Arsenic treatment did not significantly affect cellular 
ATP levels in either HepG2 cell or in primary hepatocytes, suggesting that the 
decreased coupling efficiency was not due to decreased ATP demand (Figure 5A). We 
next evaluated the effect of arsenic on the ETC. Alterations to ETC could result either 
from changes in complex expression and/or activity. Thus, in these studies we 
assessed both the expression and activity of ETC complexes.  At higher concentrations 
(> 2.5 µM) arsenic decreased complex I expression in a dose dependent manner in all 
three cell systems (Figure 4A).  Arsenic dose dependently inhibited complex I activity in 
all three cell systems tested (Figures 4B, 4C, and 4D).  These results suggest that 
increased uncoupling in response to arsenic is a result of decreased ETC function. 
These results are consistent with increased proton leak seen in both hepatoma and 
mouse primary hepatocytes in response to arsenic.  
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Figure 4.  Sodium arsenite reduces mitochondrial complex expression and 
activity in a dose dependent manner. (A) Immunoblot analysis of mitochondrial 
complex subunit proteins in HepG2 cells (left panel), human primary hepatocytes 
(middle panel, HPH) and mouse primary hepatocytes (right panel, MPH) treated with 
1.25, 2.5, 5, 10 and 20 µM of sodium arsenite for 16 h. (B – D) Mitochondrial complex I 
activity measurement in (B) HepG2 cells (C) human primary hepatocytes and (D) 
mouse primary hepatocytes treated with increasing concentrations of sodium arsenite 
for 16 h. Results are mean ± SD. Results are representative of two independent 
experiments. ;’*’ Significantly different from 0 µM arsenite treatment; P < 0.05‘#’ 
significantly different from 1.25 µM arsenite treatment; P < 0.05 
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3.4 INCREASED MITOCHONDRIAL OXIDATIVE STRESS AND INCREASED 
EXPRESSION OF ANTIOXIDANT ENZYMES IN HEPATOCYTES FOLLOWING 
ARSENIC EXPOSURE. 
As mentioned above, exposure to arsenic leads to ROS-mediated oxidative stress. Our 
results presented in Figure 4 suggest that arsenic exposure also results in mitochondrial 
dysfunction and increased proton leak. Taken together, these observations suggest that 
arsenic induced mitochondrial dysfunction and proton leak could play a causative role in 
the development of arsenic induced oxidative stress. To test this, we evaluated 
mitochondrial oxidative stress and mitochondrial function simultaneously in cells 
exposed to arsenic. For these studies we decided to use only HepG2 cells for two 
reasons 1) the pattern of arsenic induced mitochondrial dysfunction and ETC 
expression and activity were similar between the cell lines providing an opportunity to 
test the proof concept of our hypothesis and 2) primary hepatocytes were susceptible to 
toxicity associated with the triple treatment of mitoSox, arsenic and Hoechst. We 
observed that at low dose (2.5 µM), arsenic induced detectable mitochondrial oxidative 
stress as measured by mitoSox fluorescence (Figure 5B). Consistent with these 
observations, analysis of cellular oxidative stress response evaluated as a measure of 
antioxidant gene and protein expression demonstrated induction of cellular antioxidant 
response even at concentrations as low as 1 µM (Figure 6 and Figure 7). Moreover, 
cellular antioxidant response appeared to directly correlate with mitochondrial 
dysfunction and mitochondrial oxidative stress. Taken together these results suggest 
that even at low concentrations arsenic induces mitochondrial dysfunction leading to 
mitochondrial oxidative stress.  
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Figure 5. Sodium arsenate does not affect cellular ATP production but increases 
mitochondrial oxidative stress in a dose dependent manner. (A) HepG2 cells, 
human primary hepatocytes (HPH) and mouse primary hepatocytes (MPH) show no 
change in cellular ATP levels with increasing concentration of arsenite. (B) HepG2 cells 
and treated with 2.5, 5 and 20 µM of sodium arsenite for 16 h were incubated with 
MitoTracker® , MitoSOX™ and Hoechst for 20 minutes to label mitochondria (green), 
mitochondrial superoxide (red) and nuclei (blue) respectively.  Results are 
representative of three independent experiments. 
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 Figure 6. Sodium arsenite induces antioxidant gene expression in a dose 
dependent manner.  
Real-time PCR analysis of antioxidant gene expression in (A) HepG2 and (B) human 
hepatocytes exposed to increasing concentration of sodium arsenite. Results are 
representative of three independent experiments. ‘*’ Significantly different from 0 µM 
arsenite treated samples; P < 0.05; ‘#’ significantly different from 1.25 µM arsenite 
treated samples: P < 0.05. GCLC, Glutamate-cysteine ligase, catalytic subunit, GCLM 
Glutamte-cysteine ligase, regulatory subunit, GSS, Glutathione sythetase, GSTP1, 
Glutathione-S-transferase pi 1, GSTT1, Glutathione-S-transferase theta 1. 
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Figure 7. Sodium arsenite induces antioxidant protein expression in HepG2 cells 
and human and mouse primary hepatocytes. Antioxidant protein expression in (A) 
HepG2 (B) human primary hepatocytes and (C) mouse primary hepatocytes treated 
with increasing concentrations of arsenite. Antioxidant protein expression was 
measured in 15 µg of total lysate using protein specific antibodies.  Actin is used as 
loading and negative control in these experiments.  Heme-oxygenase 1 (HO-1) is used 
as a positive control.  Results are representative of three independent experiments.  
SOD2, Superoxide Dismutase 2. 
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3.5 Increased activation of glycolysis pathway in hepatocytes in response to 
arsenic treatment.  
Decreased mitochondrial function in response to arsenic in theory should result in 
decreased cellular ATP levels. However, in our studies (Figure 5A) we found no 
significant difference in ATP levels between arsenic treated and untreated cells. These 
results prompted us to test whether cells reprogram their metabolism more towards 
glycolysis in response to arsenic to compensate for the decreased mitochondrial 
function. To test this, we measured mRNA levels of glycolytic enzymes in response to 
arsenic.  In both HepG2 hepatoma cells and the human and mouse primary 
hepatocytes, arsenic treatment resulted in increased expression of Glucokinase (GK), 
Hexokinase (HK) and Phosphofructokinase (PFK), the three key enzymes involved in 
regulating glycolysis (Figure 8).  
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Figure 8. Sodium arsenite reprograms mitochondrial metabolism from oxidative 
phosphorylation to glycolysis. Real-time PCR analysis of glucokinase (GK), 
Hexokinase (HK) and Phosphofructokinase (PFG) in (A) HepG2 (B) human primary 
hepatocytes and (C) mouse primary hepatocytes exposed to increasing concentration of 
arsenite. ‘*’ Significantly different from 0 µM arsenite treatment; P < 0.05; ‘#’ Significantly 
different from 1.25 µM arsenite treatment; P < 0.05. Results representative of three 
independent experiments.  
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Chapter 4: DISCUSSION AND FUTURE DIRECTIONS 
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4.1 CONLCUSIONS 
Arsenic is a major health concern globally, with over 100 million people exposed to 
unhealthy levels of inorganic arsenic through contaminated drinking water.  Extensive 
studies have been made in understanding the mechanisms of arsenic carcinogenesis 
with the goal of designing prevention and intervention strategies and in assigning 
appropriate levels of risk to exposure.  Risk assessment has been difficult, as many 
epidemiological studies suggest that populations can be affected by arsenic-associated 
pathologies sometimes at levels below the current WHO recommendation.  Much 
progress has been made in the way of equipment capable of removing detectable levels 
of arsenic and other heavy metals from drinking water.  However, financial, material, 
and logistical constraints stand in the way of proper water purifying equipment 
becoming ubiquitous in areas with high levels of arsenic.  Given these issues, it is 
equally important to understand the mechanisms of arsenic toxicity so that prevention 
and treatment of diseases from arsenic exposure have more successful outcomes. 
The difficulty in understanding the pathogenesis of these diseases lies in the myriad of 
cellular processes that are altered or disrupted by arsenic.  Disruption of signaling 
pathways, cellular proliferation, DNA repair and methylation, interaction with thiol and 
phosphate groups, and generation of ROS are all influenced by arsenic species (13).  
This makes it difficult to elucidate which disrupted process, or processes, result in which 
diseases.  While genotoxic effects may be clearly implicated in carcinogenesis, 
production of ROS is a common factor in most, if not all diseases associated with 
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arsenic.  Therefore further studies of the sources of ROS and how they are produced is 
a worthwhile effort in investigating mechanisms of arsenic toxicity. 
Our studies suggest that mitochondria are the primary source of ROS.  Sodium arsenite 
treatment dose-dependently increased mitochondrial superoxide, and consistent with 
this, arsenic exposure resulted in altered mitochondrial bioenergetics including 
decreased respiratory reserve capacity and increased uncoupled respiration leading to 
increased proton leak.  We also confirmed previous reports that complex I of the 
electron transport chain is inhibited with increasing concentrations of arsenic, 
suggesting an additional avenue of mitochondrial dysfunction (39).  To cope with these 
stressors, we see an induction in catalase at the protein level which shows that at non-
toxic levels, cells cope with arsenic through protective mechanisms against oxidative 
stress (28).  It has previously been shown that pre-treatment with catalase alleviates 
arsenic-induced ROS in human bladder cells, and that inhibition of catalase increases 
micronuclei from arsenite (43). 
Reports indicate that glycolytic rates are increased and key regulatory enzymes are 
induced in human cells exposed to arsenic (44).  In addition to mitochondrial 
dysfunction, we also found that mRNA of key glycolytic regulatory enzymes GCK and 
HK-2 is induced.  This suggests that cells attempt to cope with energy demands by 
inducing glycolysis.  Further studies to explore how glycolytic rates and regulation 
change with arsenic are another potential avenue of investigation. 
An interesting and well-studied link between glycolysis and oxidative phosphorylation is 
the effect of arsenic on pyruvate dehydrogenase.  Arsenic is known to allosterically 
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inhibits this enzyme (21,25,45).  We showed that oxidative phosphorylation is also 
decreased by arsenic.  If mitochondria are unable to keep up with energy demands and 
the entry point of pyruvate into the TCA cycle is blocked, this could explain the induction 
of glycolytic enzymes to keep up with the need for ATP.  Disruptions in metabolism are 
well-established in the pathogenesis of metabolic diseases such as diabetes mellitus, 
and may provide insights into future therapies. 
Studying the mechanisms of toxicity by inorganic arsenic species is a complex task, as 
arsenic interacts with a large number of targets to disrupt a large number of cellular 
processes.  A common factor whether studying arsenic’s chronic carcinogenic or non-
carcinogenic effects is the production of ROS.  ROS itself reacts with multiple targets, 
giving it a prime role in genotoxic effects, protein and enzyme inhibition, and lipid 
peroxidation.  Understanding where arsenic is producing this ROS is therefore an 
important area of investigation.  Previous studies combined with our own find that 
arsenic affects mitochondrial function.  When mitochondrial function was measured, we 
found that basal respiration, ATP linked respiration, reserve capacity, and non-
mitochondrial respiration were all decreased significantly.  Concurrently, proton leak 
increased.  When mitochondrial complex function was measured, complex I was 
inhibited.  Complex I inhibition is associated with the generation of ROS (37,38).  Co-
staining mitochondrial superoxide and mitochondria showed that a large portion of the 
superoxide staining overlapped with mitochondria.  These data suggest that superoxide 
production is sourced from mitochondria, and ROS causes further damage to 
mitochondria to inhibit their function.  In turn, these malfunctioning mitochondria can 
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produce more ROS causing a loop of increasing ROS and decreasing oxidative 
phosphorylation. 
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4.2 FUTURE DIRECTIONS 
From these results, there are more studies to be conducted.  In future studies we would 
seek to confirm that superoxide is primarily sourced from mitochondria.  The hepatoma 
cell line HepG2 stained clearly with mitoSOX® and mitotracker fluorescent dye, but was 
difficult to visualize in isolated human and mouse hepatocytes.  A genetic approach to 
fluorescently label mitochondria would eliminate some of the cytotoxic effects from 
using these dyes. 
Our experiments were conducted in vitro, with either cancer cell lines (HepG2 and 
Hep3B) or isolated human and mouse hepatocytes.  Conducting our studies of 
mitochondria function and superoxide localization in an animal model is crucial to 
moving to a full understanding of arsenic toxicity in humans.  A mouse model would also 
provide a more accurate representation of chronic exposure to arsenic in humans.  In 
addition, mitochondrial function studies in cell lines from other tissues prone to arsenic-
induced carcinogenesis (skin, lung, and bladder) would provide strong evidence for 
dysfunctional mitochondria as the source for ROS in arsenic toxicity.  These 
experiments in cell lines would also provide a strong rationale for examining these 
tissues in a rodent model. 
We intend to further this study in the near future by examination of DNA damage in 
hepatocytes after arsenic treatment.  Both nuclear and mitochondrial DNA are prone to 
damage by ROS, although to varying degrees.  If ROS is primarily sourced from 
mitochondria, one could hypothesize that mitochondrial DNA would initially sustain more 
damage than nuclear DNA.  Directly measuring DNA integrity and adduct formation 
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would be telling as to which cellular compartment is exposed to higher levels of ROS.  
An indirect but important marker is measuring expression and induction of DNA repair 
enzymes.  These experiments would build on our study of mitochondrial dysfunction as 
a source of ROS production. 
An area we did not explore in these studies was the effect of cellular antioxidant 
systems in the prevention and resolution of damage from arsenic.  A future direction of 
our lab is to test if adding exogenous antioxidants or inducing antioxidant enzymes 
would prevent damage or restore function to mitochondria.  Similarly we could see if 
inhibiting antioxidants would exacerbate superoxide levels and mitochondria function.  
These studies have been conducted by others to measure protein and DNA damage, 
but not mitochondrial function. 
In areas where high arsenic levels in water are endemic, it is crucial to not only develop 
ways to purify water supplies but to understand the ways by which arsenic exerts its 
toxic effects.  By further characterizing the mechanisms of arsenic toxicity we can 
provide the basis for prevention and treatment of diseases and symptoms caused by 
arsenic. 
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